I used to use "preclinical" and "nonclinical" interchangeably. Most people in industry do. Then I spent a week reading FDA guidance documents carefully — actually carefully, not skimming — and realized these terms mean different things, and the distinction matters more than I'd assumed.
Here's the short version: "preclinical" refers to timing. "Nonclinical" refers to type. They overlap but they're not synonyms. And if you use the wrong one in an IND submission, you won't get a clinical hold over it, but you will reveal to the reviewer that you haven't thought precisely about your development program.
What FDA actually means
Nonclinical is the FDA/ICH preferred term for laboratory and animal studies. It's the word used in the CTD structure — Module 4 is literally called "Nonclinical Study Reports." ICH M3(R2) is titled "Nonclinical Safety Studies for the Conduct of Human Clinical Trials." The Nonclinical Overview in Module 2.4 uses "nonclinical" exclusively.
The word describes the type of study: not conducted in humans. In vitro cell assays, in vivo animal studies, computational models — all nonclinical. A nonclinical study can happen before clinical trials, during clinical trials, or after approval. The timing is irrelevant to the classification.
Preclinical is an informal term that refers to the development phase before clinical trials begin. It's a timing descriptor, not a study-type descriptor. When someone says "we're in preclinical," they mean "we haven't started dosing humans yet." The term encompasses nonclinical studies, but also CMC development, formulation work, assay development, and regulatory planning — none of which are "nonclinical studies" in the regulatory sense.
Why this isn't just pedantry
The distinction matters in three specific contexts:
1. CTD organization
When you're assembling an IND, knowing where things go in the CTD saves time and prevents reviewer confusion.
- Module 4: Nonclinical Study Reports — your animal pharmacology, PK, and toxicology data
- Module 2.4: Nonclinical Overview — integrated summary of Module 4 data
- Module 2.6: Nonclinical Written and Tabulated Summaries — detailed written summaries organized by discipline
Module 4 contains nonclinical study reports. Not "preclinical study reports." If you label your Module 4 sections as "preclinical," a reviewer will still know what you mean. But consistency with the CTD naming convention signals attention to detail. In a submission where details are everything, these signals compound.
2. Studies that happen during clinical development
This is where the terminology confusion causes actual problems. You're running a Phase 2 trial. You also need to conduct a 6-month repeat-dose toxicity study in rats to support Phase 3 dosing duration per ICH M3(R2) Table 1. And you're running a carcinogenicity study per ICH S1A because your drug will be used chronically.
These are nonclinical studies. They are not preclinical. They're happening in parallel with clinical trials. If your development plan refers to all animal studies as "preclinical," it creates confusion about timing — are these studies already done, or do they still need to happen?
In project planning meetings, I've seen this cause real misunderstandings. Someone says "we'll handle that in preclinical" meaning "before the IND." Someone else hears "we'll handle that with animal studies" and assumes it can happen later. The study gets planned for the wrong phase. Timelines slip.
3. Regulatory correspondence
When you write to FDA — pre-IND briefing documents, IND amendments, meeting requests — use "nonclinical." It's their language. It demonstrates that you've read their guidance documents and are communicating on their terms.
I once reviewed a pre-IND briefing document that referred to "preclinical safety studies" throughout. The FDA response used "nonclinical" in every instance. The agency didn't correct the sponsor. They just used their own term consistently. It was a subtle signal: "we know the language; do you?"
Again — nobody gets a clinical hold over terminology. But in regulatory affairs, precision is the currency of credibility.
What goes in the nonclinical package
Since we're being precise, here's what "nonclinical studies" means in the context of an IND application:
Pharmacology
- Primary pharmacodynamics — does the drug hit its target and produce the intended effect?
- Secondary pharmacodynamics — what off-target effects does it have?
- Safety pharmacology — the core battery per ICH S7A: cardiovascular (including hERG per S7B), respiratory, and CNS assessments
Pharmacokinetics
- Absorption, distribution, metabolism, excretion (ADME)
- Plasma protein binding
- Drug-drug interaction potential (in vitro CYP inhibition/induction)
- Bioanalytical method validation
Toxicology
- Single-dose toxicity (often integrated into repeat-dose studies now)
- Repeat-dose toxicity in two species
- Genotoxicity standard battery per ICH S2(R1)
- Reproductive and developmental toxicity — timing depends on clinical population
- Local tolerance — for parenteral formulations
- Immunotoxicity per ICH S8
- Carcinogenicity — typically not needed until NDA, per ICH S1A
All of these are nonclinical studies. Some happen before the IND (the Phase 1-enabling package). Some happen during clinical development. Some happen before the NDA. The timing determines when they're conducted. The type — nonclinical — stays the same.
What "preclinical" actually covers
When people say "preclinical phase," they typically mean everything that happens before the IND goes in:
- Target identification and validation — computational, in vitro
- Hit-to-lead and lead optimization — medicinal chemistry, SAR studies
- In vitro pharmacology screening — selectivity panels, functional assays
- Formulation development — getting the drug into a dosable form
- CMC development — synthesis route, analytical methods, stability
- IND-enabling nonclinical studies — the GLP tox package
- Regulatory strategy — pre-IND meeting, submission planning
- Clinical protocol development — Phase 1 design
See the mix? Some of these are nonclinical studies. Some are CMC activities. Some are clinical planning. Some are pure strategy. "Preclinical" is the umbrella term for the timing phase. "Nonclinical" is the specific category of studies involving lab and animal work.
The vocabulary chart
| Situation | Use "nonclinical" | Use "preclinical" |
|---|---|---|
| Referring to CTD Module 4 content | Yes | No |
| FDA correspondence | Yes | Avoid |
| Animal pharmacology/tox studies during Phase 2 | Yes | No |
| Describing the development phase before FIH dosing | OK (for the studies) | Yes (for the phase) |
| Internal team discussions | Either works | Common |
| Journal publications | Depends on context | Common |
| IND submission documents | Yes | Avoid |
What about "in vitro" and "in silico"?
Quick tangent because it comes up: in vitro studies (cell-based assays, tissue models) are nonclinical. In silico studies (computational modeling, QSAR, PBPK) are also nonclinical. Both can support an IND.
With the FDA's increasing acceptance of new approach methodologies (NAMs) — organ-on-chip, microphysiological systems, computational toxicology — the nonclinical category is expanding beyond traditional animal studies. The language still applies: if it's not in humans, it's nonclinical.
Why this matters for your submission
I've reviewed IND packages where the sponsor used "preclinical" and "nonclinical" interchangeably throughout the submission. In one case, Module 2.4 was titled "Preclinical Overview" instead of "Nonclinical Overview." An FDA reviewer sent a comment asking for clarification. Not a clinical hold — but an information request that delayed the review by three weeks while the team scrambled to update terminology across 40+ documents.
Three weeks doesn't sound catastrophic until you're a Series A biotech burning $400K/month in runway and your Phase 1 start date is tied to IND clearance.
The CTD structure uses "nonclinical" everywhere. Module 2.4 is "Nonclinical Overview." Module 2.6 is "Nonclinical Written and Tabulated Summaries." Module 4 is "Nonclinical Study Reports." Using "preclinical" in place of "nonclinical" in these sections signals unfamiliarity with the CTD format — not a great first impression with your reviewer.
The CRO communication angle
This comes up with CROs too. When you're contracting IND-enabling studies, the scope of work should specify "nonclinical" studies. If your CRO proposal says "preclinical package" and includes CMC analytical work alongside toxicology studies, that's mixing two CTD modules. CMC goes in Module 3. Tox goes in Module 4. They're managed by different teams, reviewed by different FDA divisions, and budgeted separately.
I've seen SOWs where "preclinical package" included formulation stability studies, animal tox, and even clinical protocol drafting. Technically everything was "before the clinic." But the billing, timelines, and deliverables were a mess because nobody separated nonclinical from CMC from clinical planning upfront.
Clean vocabulary leads to clean contracts, which leads to clean timelines.
Practical advice
For IND submissions and regulatory documents: use "nonclinical." Consistently. Every time you're tempted to write "preclinical studies," check whether you mean "studies conducted before clinical trials" (preclinical phase) or "laboratory and animal studies" (nonclinical studies). If it's the latter, use "nonclinical."
For internal communications and investor decks: "preclinical" is fine. Everyone knows what it means. The venture capital world says "preclinical-stage company" and nobody's confused. Just know that when you switch from investor-speak to FDA-speak, the vocabulary changes.
For job titles: the industry has largely settled on "VP of Preclinical Development" or "Head of Preclinical" as the role title for the person overseeing the nonclinical program. This is one of those conventions that's technically imprecise but universally understood. Don't lose sleep over it.
The point isn't to be pedantic. The point is to be precise when precision matters — which is to say, when you're talking to FDA.
Related reading:
- FDA IND Submission Checklist 2026 — what goes in each CTD module
- How to Check Preclinical Studies Against ICH Guidelines — 8-step gap analysis
- How to Write CTD Module 2.4 Nonclinical Overview — structuring Module 2.4
Want to see your nonclinical study package mapped against ICH requirements? RegFo's compliance checker organizes findings by CTD module — using the correct terminology, naturally.